netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 Formulary Chapter 12: Ear, nose and oropharynx - Full Chapter

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

12.03.05  Expand sub section  Treatment of dry mouth
12.03.05  Expand sub section  Local Treatment
12.03.05  Expand sub section  Systemic treatment
Pilocarpine eye drops 4% (dry mouth - off-label)
View adult BNF View SPC online
Restricted Drug Restricted

Approved off-label indication:

  • For symptoms of dry mouth in patients with Sjögren's syndrome or following irradiation for head and neck cancer (alternative when there are supply issues with pilocarpine tabs) Given orally.

Starting dose = 3 drops of 4% (6mg) three times a day

Pilocarpine tabs
View adult BNF View SPC online
Restricted Drug Restricted For symptoms of dry mouth and dry eyes in patients with Sjögren's syndrome 
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

Amber 1

Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

Amber 2

Specialist initiation followed by maintenance prescribing in primary care  

Amber 3

Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  


Specialist and non-specialist initiation  


Not recommended for prescribing